

## How much protein in the critical illness

Pierre Singer, MD
Institute for Nutrition Research and Critical Care Department
Rabin Medical Center
Tel Aviv University
Israel




From Singer P: Nutrition in the ICU: beyond physiology. Karger Publisher




# Energy and protein administered in Nutrition Day study

- From 4,125 patients:
- Protein given 60 ± 31 g/d
- Lipid given 53 ± 31 g/day
- Carbohydrates 176 ± 87 g/d
- Total median calories: 1,500 kcal/d




icu stay <2 days & not ventilated (1)</li>
 icu stay ≥ 2 days & not ventilated (3)
 icu stay ≥ 2 days & ventilated (4)


# Message: Give enough protein to fight anabolism resistance



# The effects of bed rest INACTIVITY




## CHANGES OF MUSCLE AND VISCERAL PROTEIN CONTENT IN SEVERELY SEPTIC PATIENTS DURING THE FIRST DAYS AFTER THE ONSET OF PERITONITIS




- **■** Skeletal muscle protein
- **▲** Visceral protein

Plank et al, Ann Surg 1998



### EFFECTS OF 2-WEEK BED REST ON INFLAMMATORY MEDIATORS IN HEALTHY YOUNG VOLUNTEERS






### Activated Protein Synthesis and Suppressed Protein Breakdown Signaling in Skeletal Muscle of Critically III Patients

Jakob G. Jespersen<sup>1</sup>\*, Anders Nedergaard<sup>1</sup>, Søren Reitelseder<sup>1</sup>, Ulla R. Mikkelsen<sup>1</sup>, Kasper J. Dideriksen<sup>1</sup>, Jakob Agergaard<sup>1</sup>, Frederik Kreiner<sup>2</sup>, Frank C. Pott<sup>3</sup>, Peter Schjerling<sup>1</sup>, Michael Kjaer<sup>1</sup>


**Table 3.** Circulating IGF-1, markers of systemic inflammation, proteins and metabolites.

Variable	Control subjects (n = 12)	ICU patients (n = 12)	% Difference
IGF-1, μg/l	132±14	76±14†	-43
Inflammatory markers			
Leukocytes, 10 <sup>9</sup> /l	ND, normal range: 3.0-9.0	16.3±3.3	
CRP, mg/l	ND, normal <10	134±28	
TNF-α, pg/ml	3.9±0.5	27.3±8.4*	+605
IL-6, pg/ml	6.3±1.5	1096±366*	+17371
IL-8, pg/ml	3.8±0.5	201±91 <sup>1</sup>	+5246
IL-10, pg/ml	13.9±2.7	607±262*	+4258
MCP-1, pg/ml	266±28	1438±213‡	+440
Proteins and metabolites			
Serum albumin, g/l	ND, normal range: 34–48	21.1±1.6	
Urea, mmol/l	ND, normal range: 3.1-8.1	16.9±4.3	
Creatinine, umol/l	ND, normal range: 45–105	160+33	

## Message: Give enough protein to fight anabolic resistance




#### Hypercatabolic Syndrome / Insulin Resistance




#### Physical inactivity and muscle weakness in the critically ill

Melissa A. Chambers, PhD; Jennifer S. Moylan, PhD; Michael B. Reid, PhD



### Oxidative stress and disuse muscle atrophy: cause or consequence?


Scott K. Powers<sup>a</sup>, Ashley J. Smuder<sup>a</sup>, and Andrew R. Judge<sup>b</sup>








### Myopathic characteristics in septic mechanically ventilated patients

Claire E. Baldwin<sup>a,b</sup> and Andrew D. Bersten<sup>c,d</sup>









Hyperglycemia exacerbates muscle protein catabolism in burn-injured patients

Dennis C. Gore, MD; David L. Chinkes, PhD; David W. Hart, MD; Steven E. Wolf, MD; David N. Herndon, MD; Arthur P. Sanford, MD





Figure 1. Negative net balance reflects net catabolism. *Phe*, phenylalanine; mean  $\pm$  sd; \*p < .05in comparison with normal.

#### Inverse Regulation of Protein Turnover and Amino Acid Transport in Skeletal Muscle of Hypercatabolic Patients

GIANNI BIOLO, R. Y. DECLAN FLEMING, SERGIO P. MAGGI, THUAN T. NGUYEN, DAVID N. HERNDON, AND ROBERT R. WOLFE

J Clin Endocrinol Metab, July 2002, 87(7):3378–3384



# Immobilization induces anabolic resistance in human myofibrillar protein synthesis with low and high dose amino acid infusion

Elisa I. Glover<sup>1</sup>, Stuart M. Phillips<sup>1</sup>, Bryan R. Oates<sup>1</sup>, Jason E. Tang<sup>1</sup>, Mark A. Tarnopolsky<sup>2</sup>, Anna Selby<sup>3</sup>, Kenneth Smith<sup>3</sup> and Michael J. Rennie<sup>3</sup>





Figure 2. Quadriceps femoris cross-sectional area

Figure 4. Pooled (from both low and high infused groups) resting fasted myofibrillar protein fractional synthetic rate (FSR)

## Message: Give enough protein to fight anabolism resistance



### Loss of muscle mass in ICU patients

Daily UL measurement of upper arm, forearm and thigh for a median of 7 days (N=50).

Admission APACHE II score: 17. Mortality: 28% Reid et al. 2004; Clin Nutr 23: 273-280

Muscle thickness decreased by an average of 1.6% per day

With 6 kg metabolizable protein in lean body mass: ≈ 100g/day


After 10 days: 16% muscle loss ≈ 1000 g protein ≈ 5 kg lean body mass

#### REE in 24 patients:

10 patients in positive energy balance: 1.1 % per day 14 patients in negative energy balance: 1.3 % per day

### Muscle Wasting and Early ® Mobilization in Acute Respiratory Distress Syndrome

Christopher J. Walsh, MD, FRCPC<sup>a</sup>, Jane Batt, MD, FRCPC, PhD<sup>a</sup>, Margaret S. Herridge, MD, FRCPC, MPH<sup>b</sup>, Claudia C. Dos Santos, MD, FRCPC, MSc<sup>a</sup>,\*



#### Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

### Acute Skeletal Muscle Wasting in Critical Illness

Zudin A. Puthucheary, MRCP; Jaikitry Rawal, MRCS; Mark McPhail, PhD; Bronwen Connolly, BSc;

Gamunu Ratnayake, MRCP; Pearl Chan, MBBS; Nicholas S. Hopkinson, PhD; Rahul Padhke, PhD; Tracy Dew, MSc;

Paul S. Sidhu, PhD; Cristiana Velloso, PhD; John Seymour, PhD; Chibeza C. Agley, MSc; Anna Selby, PhD;

16 (7-80)

19 (30.2)

0 (0-6)

0(0-800)

0 (0-4533)

30 (11-334)

Marie Limb, PhD; Lindsay M. Edwards, PhD; Kenneth Smith, PhD; Anthea Rowlerson, PhD;

ICU length of stay, median (range), d

Renal replacement therapy, No. (%)

median (range), d

Total by day 10

Day 1

Use of neuromuscular blocking agents,

Hydrocortisone dose, median (range), mgb

Hospital length of stay, median (range), d

Michael John Rennie, PhD; John Moxham, PhD; Stephen D. R. Harridge, PhD; Nicholas Hart, PhD;

Hugh E. Montgomery, MD JAMA. 2013;310(15):1591-1600.

Table, Baseline Characteristics of Patients

All Patients	Serial Muscle Biopsies and Ultrasound	Muscle Ultrasound Alone	Stable Isotope Incorporation
(N = 63)	(n = 42)	(n = 21)	(n = 11)

	All Patients (N = 63)	Biopsies and Ultrasound (n = 42)	Ultrasound Alone (n = 21)	Stable Isotope Incorporation (n = 11)
Age, mean (95% CI), y	54.5 (50.0-59.1)	55.3 (49.4-61.1)	53.1 (45.4-60.1)	62.7 (50.1-75.4)
Malo soy No. (%)	27 (59 7)	20 (71 A)a	7 (21 2)	0 (81 8) <sup>a</sup>

	(14 - 65)	(11 - 42)	(11 - 21)	(11 - 11)
Age, mean (95% CI), y	54.5 (50.0-59.1)	55.3 (49.4-61.1)	53.1 (45.4-60.1)	62.7 (50.1-75.4)
Male sex, No. (%)	37 (58.7)	30 (71.4) <sup>a</sup>	7 (31.3)	9 (81.8) <sup>a</sup>
Haspital langth of stay prior to ICH admis	1 /1 /5\	1 (1 ()	1 /1 /5)	1 (1 ()

. 3 -,	( ,		,	(,
Male sex, No. (%)	37 (58.7)	30 (71.4) <sup>a</sup>	7 (31.3)	9 (81.8) <sup>a</sup>
Hospital length of stay prior to ICU admission, median (range), d	1 (1-45)	1 (1-6)	1 (1-45)	1 (1-6)

Male sex, No. (%)	37 (58.7)	30 (71.4) <sup>a</sup>	7 (31.3)	9 (81.8)ª
Hospital length of stay prior to ICU admission, median (range), d	1 (1-45)	1 (1-6)	1 (1-45)	1 (1-6)
Period ventilated, median (range), d	10 (2-62)	8.5 (2-62)	10 (4-24)	12 (2-62)

15.5 (7-80)

29.5 (11-212)

13 (31.0)

0 (0-6)

0(0-800)

0(0-4533)

17 (7-73)

33 (13-334)

6(29.0)

0(0-5)

0(0-400)

0 (0-3360)

18 (8-80)

50 (17-212)


4 (36.4)


0 (0-6)

200 (0-800)


450 (0-4533)

	APACHE II score, mean (95% CI)	23.5 (21.9-25.2)	23.3 (21.3-25.3)	24 (20.1-27.2)	27 (22.9-31.3)
	SAPS II score, mean (95% CI)	45.5 (41.8-49.3)	43.4 (39.2-47.6)	49.7 (42.0-57.4)	47 (39.6-54.4)
	Survival, No. (%)				
	ICU	61 (97)	40 (95)	21 (100)	10 (91)
	Hospital	56 (89)	37 (88)	19 (90)	9 (82)












#### B Leg protein balance (n = 11)



Time From Admission






From Kreyman et al Clin Nutr 2013


### Qualitative Ultrasound in Acute Critical Illness Muscle Wasting CCM 2015

Zudin A. Puthucheary, PhD<sup>1,2,3</sup>; Rahul Phadke, FRCPath<sup>4</sup>; Jaikitry Rawal, MRCS<sup>1</sup>; Mark J. W. McPhail, PhD<sup>5,6</sup>; Paul S. Sidhu, FRCR<sup>7</sup>; Anthea Rowlerson, PhD<sup>2</sup>; John Moxham, MD<sup>8</sup>; Stephen Harridge, PhD<sup>2</sup>; Nicholas Hart, PhD<sup>9</sup>; Hugh E. Montgomery, MD<sup>1</sup>



#### **Skeletal Muscle Glycogen Content Score Via U/S**

#### Athlete Before Competition= 90 Moderately Active at Rest= 65






#### **Critically III Patient= 0**




Scale: 0-90



# Long-Term Association Between Frailty and Health-Related Quality-of-Life Among Survivors of Critical Illness: A Prospective Multicenter Cohort Study Critical Care Medicine 2015

Sean M. Bagshaw, MD, MSc<sup>1</sup>; H. Thomas Stelfox, MD, PhD<sup>2</sup>; Jeffrey A. Johnson, PhD<sup>3</sup>; Robert C. McDermid, MD<sup>1</sup>; Darryl B. Rolfson, MD<sup>4</sup>; Ross T. Tsuyuki, PharmD, MSc<sup>5,6</sup>; Ouazi Ibrahim, MSc<sup>6</sup>; Sumit R. Maiumdar, MD, MPH<sup>5</sup>






Figure 3. Health-related quality-of-life assessed by the EuroQol (EQ)-visual analogue scale (VAS) at 6 and 12 mo stratified by Clinical Frailty Scale score (CFS).






Figure 4. Summary of problems, assessed by the EuroQol-5Q, reported by survivors at 6 and 12 mo stratified by frailty status.

### Critical illness: Infections/Immobility/Mechanical ventilation




# Message: Give enough protein to fight anabolism resistance




### FFM & Energy requirements

Wang et al. Am J Physiol Endocrinol Metab 2000; 279: E539-E545



```
\begin{aligned} \text{REE} &= k_1 \times \text{liver} + k_2 \times \text{kidney} + k_3 \times \text{brain} + k_4 \times \text{heart} + k_5 \times \text{SM} + k_6 \times \text{AT} + K_7 \\ &\times (\text{lung + thyroid + adrenal + spleen + gut + skin + blood + skeleton}) \\ &= 200 \times (0.0491 \times \text{BM}^{0.70}) + 440 \times (0.0089 \times \text{BM}^{0.71}) + 240 \times (0.1025 \times \text{BM}^{0.71}) \\ &+ 440 \times (0.006 \times \text{BM}^{0.98}) + 13 \times (0.468 \times \text{BM}^{0.99}) + 4.5 \times (0.075 \times \text{BM}^{1.19}) \\ &+ 12 \times (0.0092 \times \text{BM}^{0.92} + 0.0001 \times \text{BM}^{0.92} + 0.0003 \times \text{BM}^{0.80} + 0.003 \times \text{BM}^{1.02} \\ &+ 0.075 \times \text{BM}^{0.94} + 0.106 \times \text{BM}^{0.94} + 0.069 \times \text{BM}^{1.02} + 0.061 \times \text{BM}^{1.09}) \end{aligned}
```


## Metabolism & Age & Gender



Short et al. Am J Physiol Endocrinol Metab 2004; 286: E92-E101

# Exploitation of Diagnostic Computed Tomography Scans to Assess the Impact of Nutrition Support on Body Composition Changes in Respiratory Failure Patients

Carol A. Braunschweig, PhD, RD<sup>1</sup>; Patricia M. Sheean, PhD, RD<sup>2</sup>; Sarah J. Peterson, MS, RD<sup>3</sup>; Sandra Gomez Perez, MS, RD<sup>2</sup>; Sally Freels, PhD<sup>4</sup>; Karen L. Troy, PhD<sup>5</sup>; Folabomi C. Ajanaku, BS<sup>6</sup>; Ankur Patel, MD<sup>7</sup>; Joy S. Sclamberg, MD<sup>7</sup>; and Zebin Wang, PhD<sup>8</sup>



**Figure 1.** Representative patient showing transverse computed tomography image at the 3rd lumbar vertebrae demonstrating subcutaneous adipose tissue (light blue), abdominal skeletal muscle (red), intermuscular fat (green) and visceral fat (yellow).


# Weight loss and loss of function

≈ 20 % loss of body protein related to	
Intracell K <sup>+</sup> , mmol/l	133 (vs. 152; P=0.05)
Grip strength, %	65
Resp muscle strength, %	<b>79</b>
Type 1 muscle fibers (hi ox, lo glyc), area	41 (vs. 73; P<0.001)
Type 2 muscle fibers (lo ox, hi glyc), area	28 (vs. 73; P<0.001)

## Nutritional Status and Mortality in the Critically III\*

Kris M. Mogensen, MS, RD, LDN, CNSC<sup>1</sup>; Malcolm K. Robinson, MD<sup>2</sup>; Jonathan D. Casey, MD<sup>3</sup>; Nicole S. Gunasekera, BA<sup>4</sup>; Takuhiro Moromizato, MD<sup>5</sup>; James D. Rawn, MD<sup>2</sup>;

Characteristics	Total	n (%) Alive at 30 D	n (%) Expired at 30 D	p	Unadjusted OR (95% CI) for 30-D Mortality
Nutrition status				< 0.001	
Malnutrition absent, n (%)	2,123 (32.6)	1,809 (34.3)	314 (25.2)		1.00 (Referent)
Malnutrition absent	47 (0.7)				
At risk for malnutrition	2,076 (31.9)				
Nonspecific malnutrition, n (%)	3,641 (55.9)	2,931 (55.6)	710 (57.0)		1.40 (1.21-1.61)
Nonspecific protein- energy malnutrition	3,641 (55.9)				
Protein-energy malnutrition, n (%)	754 (11.6)	533 (10.1)	221 (17.8)		2.39 (1.96–2.91)
Mild protein-energy malnutrition	324 (5.0)				
Moderate protein-energy malnutrition	152 (2.3)				
Severe protein-energy malnutrition	33 (0.5)				




# How much protein should we administer?




# PROTEIN REQUIREMENT IN CRITICAL ILLNESS AT ADEQUATE ENERGY INTAKE

Wolfe et al., Ann Surg 1983; *Ishibashi et al., Crit Care Med 1998*Hoffer Am J Clin Nutr 2003



#### Protein<sub>eq</sub> balance according to < or >1.3g/kg given



### How much protein?

When PN is indicated, a balanced amino acid mixture should be infused at approximately 1.3 – 1.5 g/kg ideal body weight per day in conjunction with an adequate energy supply.

(Grade B)

- Balanced amino acids mixture is similar to essential amino acid requirements in healthy subjects
- Lean tissue loss is unavoidable in patients with severe trauma or sepsis
- The loss is minimized with 1.3 1.5 g/kg per day



# Does feeding induce maximal stimulation of protein balance?

Felix Liebau, Åke Norberg, and Olav Rooyackers






FIGURE 1. Protein balance in relation to amino acid intake in critically ill patients treated in the ICU from four different studies. Whole-body protein balance was measured using isotopically labeled phenylalanine. (Reproduced with

### Influence of Aging on Nitrogen Accretion During Critical Illness


Roland N. Dickerson, PharmD<sup>1</sup>; George O. Maish III, MD<sup>2</sup>; Martin A. Croce, MD<sup>2</sup>; Gayle Minard, MD<sup>2</sup>; and Rex O. Brown, PharmD<sup>1</sup>






#### Hypocaloric, High-Protein Nutrition Therapy in Older vs Younger Critically Ill Patients With Obesity

Roland N. Dickerson, PharmD<sup>1</sup>; Theresa L. Medling, PharmD<sup>1</sup>; Ashley C. Smith<sup>1</sup>; George O. Maish III, MD<sup>2</sup>; Martin A. Croce, MD<sup>2</sup>; Gayle Minard, MD<sup>2</sup>; and Rex O. Brown, PharmD<sup>1</sup>





Close to recommended caloric and protein intake by enteral nutrition is associated with better clinical outcome of critically ill septic patients: secondary analysis of a large international nutrition database

Gunnar Elke<sup>1</sup>, Miao Wang<sup>2</sup>, Norbert Weiler<sup>1</sup>, Andrew G Day<sup>2</sup> and Daren K Heyland<sup>2\*</sup>

Table 3 Relationship between enteral nutrition and 60-day mortality

		Unadjusted			Adjusted	
	Odds ratio	95% CI	P value	Odds ratio	95% CI	P value
A: Total study pop	oulation (n = 2,270)					
Energy intake						
Per 1,000 kcal	0.51	(0.41-0.64)	<0.001	0.61	(0.48-0.77)	<0.001
Protein intake						
Per 30 gram	0.70	(0.61-0.80)	< 0.001	0.76	(0.65-0.87)	< 0.001
B: Sensitivity analy	ysis (n = 1,560)					
Energy intake						
Per 1,000 kcal	0.56	(0.44-0.71)	<0.001	0.61	(0.48-0.79)	< 0.001
Protein intake						
Per 30 gram	0.72	(0.62-0.83)	< 0.001	0.75	(0.64-0.87)	< 0.001

M.J. Allingstrup et al. /

Clin Nutr. 2012 Aug;31(4):462-8





Figure 1. Hazard ratios for women according to energy goal reached and protein goal reached or not.



## RetroTICACOS

7538 screened



1420 pts with one measurement



1171 pts included

6 patients incomplete background data 243 not full filling length of stay follow up criteria

Retro TI	CACOS: 1	.062 P	ATIENTS	MEAS	SURED
Parameter	Underfed		Tight		
	(N=587)	SD	(n=475)	SD	P value
	Mean		Mean		
Age (years)	56.1	18.7	59.3	18.8	0.007

287 (59.2%)

78.3

1.69

22.8

8.0

18.8

0.09

**7.4** 

3.2

0.001

0.001

<0.001

0.65

0.71

22.9

0.1

7.2

3.8

398 (69.0%)

82.8

1.71

22.5

8.1

**Gender M(%)** 

Weight (kg)

Height (m)

HB in kcal/d


**APACHE II** 


**SOFA** 


# 60 days mortality Better survival in the tight group

- OR of 0.73 [95% CI 0.55-0.97], p=0.03
- cox regression, survival analysis had an OR of 0.75 [95% CI 0.58-0.94]. P=

 The other parameters with a strong correlation with mortality were albumin and SOFA score (0.77 and 1.14 respectively)







# Early Parenteral Nutrition in Critically III Patients With Short-term Relative Contraindications to Early Enteral Nutrition

A Randomized Controlled Trial

Gordon S. Doig, PhD

**Importance** Systematic reviews suggest adult patients in intensive care units (ICUs)

Figure 2. Enteral and Parenteral Nutrition Delivery Process Measures for Patients Remaining in the Study ICU




Table 2. Mortality, Quality of Life, and Length of Stay


	Standard Care (n = 680) <sup>a</sup>	Early PN (n = 678) <sup>a</sup>	Risk Difference, % (95% CI)	Odds Ratio (95% CI)	P Value
Deaths before study day 60, No. (%)	155 (22.8)	146 (21.5)	-1.26 (-6.6 to 4.1)	0.93 (0.71 to 1.21)	.60
Covariate-adjusted deaths before study day 60 <sup>b</sup>			0.04 (-4.2 to 4.3)	1.00 (0.76 to 1.31)	>.99
Quality of life and physical function, mean (SD) <sup>c</sup>	(n = 525)	(n = 532)	Differenc	e (95% CI)	
RAND-36 general health status <sup>d</sup>	45.5 (26.8) (n = 516)	49.8 (27.6) (n = 525)	4.3 (0.95	to 7.58)	.01
ECOG performance status <sup>e</sup>	1.53 (1.1) (n = 516)	1.51 (1.1) (n = 525)	-0.02 (-0.15 to 0.11)		.70
RAND-36 physical function <sup>f</sup>	40.7 (29.6) (n = 513)	42.5 (30.8) (n = 524)	1.8 (-1.8	35 to 5.52)	.33
Discharge status and length of stay	(n = 682)	(n = 681)	Differenc	e (95% CI)	
ICU stay, mean (95% CI), d	9.3 (8.9 to 9.7)	8.6 (8.2 to 9.0)	-0.75 (-1.	47 to 0.04)	.06
Deaths before ICU discharge, No. (%)	100 (14.66)	81 (11.89)	-2.77% (-8.	08% to 2.52%)	.15
Hospital stay, mean (95% CI), d	24.7 (23.7 to 25.8)	25.4 (24.4 to 26.6)	0.7 (-1.	4 to 3.1)	.50
Deaths before hospital discharge, No. (%)	151 (22.1)	140 (20.6)	-1.58% (-6.	91% to 3.69%)	.51


# The Association Between Nutritional Adequacy and Long-Term Outcomes in Critically III Patients Requiring Prolonged Mechanical Ventilation: A Multicenter Cohort Study\*

Xuejiao Wei, MSc<sup>1</sup>; Andrew G. Day, MSc<sup>1,2</sup>; Hélène Ouellette-Kuntz, PhD<sup>1</sup>; Daren K. Heyland, MD, MSc<sup>2,3</sup>

TABLE 1. (Continued). Patient Baseline Characteristics and Short-Term Clinical Outcomes

		Nutritional Adequacy <sup>a</sup>			
Variable	Overall	Low (0% and ≤ 50%)	Moderate (≥ 50% and < 80%)	High (≥ 80%)	₽ <sup>b</sup>
Short-term clinical outcomes					
ICU length of stay					
Median (interquartile range)	18 (13-29)	18 (13–28)	19 (13–31)	18 (12-29)	
Mechanical ventilation duration					
Median (interquartile range)	15 (11–25)	15 (10-23)	15 (11–25)	15 (11–25)	
ICU mortality <sup>c</sup> (%)	123 (26)	47 (26)	62 (27)	14 (23)	0.63
Hospital mortality (%)	151 (32)	58 (32)	75 (32)	18 (29)	0.85






**Figure 2.** Crude (**A**) and adjusted (**B**) survival curves stratified by nutritional adequacy groups in 475 patients who were mechanically ventilated in the ICU for more than 8 days. Adjusted covariates include age, Acute Physiology and Chronic Health Evaluation II score, baseline Sequential Organ Failure Assessment, Charlson Comorbidity Index, admission category, primary ICU diagnosis, body mass index, and region.

TABLE 4. Estimates of the Effect of Nutritional Adequacy on 36-Item Short-Form Health Survey Scores

	Nutritional Adequacy <sup>a</sup> per 25% Increase			
36-Item Short-Form Health Survey	Crude Estimate <sup>b</sup> (95% CI)	P	Adjusted Estimate <sup>b,c</sup> (95% CI)	p
Physical Functioning				
$3 \text{ mo } (n = 179)^d$	7.7 (2.3–13.1)	0.006	7.3 (1.4–13.2)	0.02
6 mo $(n = 202)^d$	5.3 (0.0-10.5)	0.05	4.2 (-1.3 to 9.6)	0.14
Role Physical				
$3 \text{ mo } (n = 178)^d$	8.3 (3.0-13.5)	0.002	8.3 (2.7-14.0)	0.004
6 mo $(n = 202)^d$	5.0 (-0.2 to 10.2)	0.06	3.2 (-2.3 to 8.5)	0.25
Physical Component Scale				
$3 \text{ mo } (n = 175)^d$	1.8 (-0.1 to 3.7)	0.06	1.8 (-0.2 to 3.8)	0.07
6 mo $(n = 200)^d$	1.8 (-0.2 to 3.7)	0.07	1.3 (-0.7 to 3.3)	0.19

and the first of the control of the



# Exercise to fight anabolic resistance




Table 2 Specific treatment modalities for early rehabilitation in the ICU studied in positive prospective trials					
Treatment Modality/Intervention	Study/Study Design	Patient Population	Primary Outcome/Results		
UE/LE exercise	Schweickert et al, <sup>89</sup> 2009 RCT N = 104	Sedated adult ICU patients on MV <72 h	Significantly higher rate of return to independent functional status at hospital discharge (59% in treatment group vs. 35%; P<.02)		
Bed exercises and mobilization	Malkoc et al, 120 2009 N = 510 Prospective intervention group Retrospective case group	Multidisciplinary internal medicine ICU: 51% of patients required MV	Decreased length of MV and ICU stay in intervention group vs controls		
Early activity protocol (sitting on chair or edge of bed; ambulation with walker)	Thomsen et al, <sup>79</sup> 2008 Before-after cohort study N = 104	Patients in RICU requiring >4 d of MV	Significant increase in rate of ambulation in patient cohort transferred to an RICU implementing early activity protocol vs pretransfer levels		
Cycle ergometry (passive or active) combined with UE/LE exercise	Burtin et al, <sup>83</sup> 2009 RCT N = 67	Single-center surgical and medical ICU patients with expected prolonged stay (at least 12 d after admission to ICU)	Significantly increased 6MWD, quadriceps force, and physical functioning at hospital discharge in treatment group vs controls		
IMT with threshold inspiratory device	Martin et al, <sup>97</sup> 2011 RCT N = 69	Single-center medical and surgical ICU patients with failure to wean from MV with usual care	IMT significantly improved MIP and weaning outcome compared with sham treatment		
NMES	Routsi et al, <sup>85</sup> 2010 RCT N = 52	Patients in the ICU with APACHE score ≥13 capable of assessment with MRC	MRC score was significantly higher in patients with NMES compared with patients who received sham treatment		

Abbreviations: 6MWD, 6MW distance; APACHE, acute physiology and chronic health evaluation; IMT, inspiratory muscle training; LE, lower extremity; MIP, maximal inspiratory pressure; RICU, respiratory ICU; UE, upper extremity.

# Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men

Vinod Kumar<sup>1</sup>, Anna Selby<sup>1</sup>, Debbie Rankin<sup>1</sup>, Rekha Patel<sup>1</sup>, Philip Atherton<sup>1</sup>, Wulf Hildebrandt<sup>1</sup>, John Williams<sup>2</sup>, Kenneth Smith<sup>1</sup>, Olivier Seynnes<sup>3</sup>, Natalie Hiscock<sup>4</sup> and Michael J. Rennie<sup>1</sup>



#### M Davies et al ICM submitted





FIGURE 5. Meta-regression analysis of effect of average protein delivery on mortality





??? ????? ????? mp4



Patient Story Timothee\_Mpeg4 H264\_8894.mp4

Combining nutrition and exercise to optimize survival and recovery from critical illness: Conceptual and methodological issues

Daren K. Heyland <sup>a, \*</sup>, Renee D. Stapleton <sup>b</sup>, Marina Mourtzakis <sup>c</sup>, Catherine L. Hough <sup>d</sup>, Peter Morris <sup>e</sup>, Nicolaas E. Deutz <sup>f</sup>, Elizabeth Colantuoni <sup>g</sup>, Andrew Day <sup>a</sup>, Carla M. Prado <sup>h</sup>, Dale M. Needham <sup>i</sup>

#### Multimodal Intervention Anticatabolic/ Anti-inflammatory **Exercise** Nutrition **Therapies** - Adequate nutrition - PUFA - Resistance training Beta blockers support Cycling - Amino acids (propranolol) - Neuromuscular - Non-steroidal - HMB electrical stimulation anti-inflammatory agents - PUFA - Graduated mobility

Winning the war against ICU-acquired weakness: new innovations in nutrition and exercise

physiology

Paul E Wischmeyer<sup>1\*</sup> and Inigo San-Millan<sup>2</sup>



## Ensuring Optimal Survival and Post-ICU Quality of Life in High-Risk ICU Patients: Permissive Underfeeding Is Not Safe!\* Paul E. Wischmeyer, MD

Critical Care Medicine August 2015 • Volume 43 • Number 8



TABLE 1. Recent Trials in ICU Nutrition Delivery

**Early versus Late** 

Study Outcomes	Parenteral Nutrition in Critically III Adults (6)	EDEN Trial (Pilot) (4)	(Full Randomized Controlled Trial) (3)	Arabi Trial (2)
Age (mean)	64	53	52	51
ICU LOS	3.5			13.1
Hospital LOS	15			
Mechanical ventilation days	2	5.6	5	11.9
Mortality, %				
ICU	6.2			19.6
Hospital	10.65	21		36
Postdischarge	11.2		22.7	38.6
Primary outcomes	Significant reduced LOS in ICU for late PN (median, 3 d) vs early PN (median, 4 d)	No outcome changes in trophic vs full feeding groups for ventilation days, mortality, or infection	No outcome changes in trophic vs full feeding groups for ventilation days, mortality, or infection	Nonsignificant trend to lower 28-d mortality for trophic (18.3%) compared with target feeding (23.3%) $(p < 0.07)$
Secondary outcomes	Significant higher infectious complications, duration of MV, and hospital LOS for early PN	Full feeding group more likely to be discharged home then rehabilitation unit (p < 0.04)	No change in HRQoL at 12 mo	No difference in LOS or duration of MV
Limitations	> 50% of patients with short stays (< 3 d) and with no indication for nutrition	Primarily young, obese patients with short duration of stay	Primarily young, obese patients with short duration of stay	Very small difference in caloric intake between trophic and full feeding group (~10% difference: 1,067±306 vs 1,252±432 kcal/d)
	Potential for overfeeding with glucose infusions in early PN group	Low protein delivery (0.8 g/kg/d) in both groups (including full feed group)	Low protein delivery (0.6-0.8 g/kg/d) in both groups (including full feed group)	Low protein intake (0.6 g/kg/d in all patients)
	Low protein intake (0.8 g/kg/d in all patients)			

Trials Not Supporting Goal (> 80% kcal/d) Nutritional Delivery in ICU

**EDEN Trial** 


#### Trials Supporting Goal (> 80% kcal/d) Nutritional Delivery in ICU

Early PN (7)	The Tight Calorie Control Trial (9)	SPN (8)	Wei et al (5)
69	61	61	62
9	12	13	18
25	25	31.5	
6.9	10.75	6.64	15
21	25.4 38.3 47	10 24 23	26 32
No significant change in crude day 60 mortality (standard care [22.8%] vs early PN [21.5%])	Significant lower hospital mortality for goal calorie group (28.5%) vs underfed control group (48.2)	Significant reduced nosocomial infections for EN + SPN (27%) vs EN (38%) after day 9	Significant improved survival and 3 mo HRQoL with improved nutrition delivery
Significant shorter duration of MV Improved HRQoL for early PN group No change in infection in PN vs EN	Longer duration of MV and ICU LOS, and higher infection rate for goal calorie study group	No significant difference in the ICU LOS, hospital LOS, or mortality	Significant improvement in HRQoI in medical ICU patients at 3 and 6 mo with improved nutrition delivery
Many gastrointestinal surgical patients	Did not account for nonnutrition energy delivery	No difference in infections over entire study period	Observational trial
	Metabolic cart energy goals (may not be widely applicable currently)	Metabolic cart energy goals (may not be widely applicable currently)	Protein intake not able to be quantified

Pierre Singer Jonathan Cohen

### Nutrition in the ICU: proof of the pudding is in the tasting

Recommendations based on 25 kcal/kg/day for an adult weighting 77 kg





### To Implement Guidelines: The (Bad) Example of Protein Administration in the ICU

Pierre Singer, MD; and Jonathan D. Cohen, MD


**Table 1.** Protein Intake Inspired by Recent Prospective Nutrition Studies in the Intensive Care Unit.

Studies	Protein Intake in Control Group	Protein Intake in Study Group
Van den Berghe et al,9 g/kd/d	0.85	0.80
Rice et al, 10 g/d	11	54
Arabi et al, 11 g/d	47.5	43.6
Singer et al, 12 g/d (g/kg/d)	53 (0.68)	76 (1)
Heidegger et al,13 g/d	56	79
Casaer et al, 14 g/d	<60	<60
Weijs et al,8 g/d	67	89

Adapted from Singer and Pichard.<sup>25</sup>

Journal of Parenteral and Enteral Nutrition Volume XX Number X Month 2013 1-3 © 2013 American Society for Parenteral and Enteral Nutrition DOI: 10.1177/0148607113481063 jpen.sagepub.com hosted at

## Protein intake observed vs GL



1.2 g/kg/d 77kg


### How to improve?

- Increase quantity
- Improve quality
- Better glucose control
- Exercise




Current recommended parenteral protein intakes do not support protein synthesis in critically ill septic, insulin-resistant adolescents with tight glucose control

Sascha C. A. T. Verbruggen, MD, PhD; Jorge Coss-Bu, MD; Manhong Wu, PhD; Henk Schierbeek, PhD; Koen F. M. Joosten, MD, PhD; Archana Dhar, MD; Johannes B. van Goudoever, MD, PhD; Leticia Castillo, MD, FCCM




Whey protein ingestion in elderly results in greater muscle protein accrual than ingestion of its constituent essential amino acid content


Christos S. Katsanos<sup>a,\*</sup>, David L. Chinkes<sup>b</sup>, Douglas Paddon-Jones<sup>c</sup>, Xiao-jun Zhang<sup>b</sup>, Asle Aarsland<sup>d</sup>, and Robert R. Wolfe<sup>e</sup>



# Nutritional regulation of muscle protein synthesis with resistance exercise: strategies to enhance anabolism

Tyler A Churchward-Venne, Nicholas A Burd and Stuart M Phillips\*





### Exercise





### Conclusions



- Muscle atrophy is linked to anabolism resistance
- High amount of protein is needed (>1.5 g/d) and some patients need more
- Requirements adapted to weight, age, metabolic status: not a unique recommendation!
- Exercise may decrease protein catabolism and improve anabolic resistance.